Stock Data
$0.05 (3.79%)
Asset Type
Common Stock
Exchange
NASDAQ
Currency
USD
Country
USA
Sector
HEALTHCARE
Industry
DIAGNOSTICS & RESEARCH
Opko Health Inc is a diverse healthcare company that operates globally, offering a mix of diagnostic and pharmaceutical services. It runs BioReference Laboratories, providing a wide range of laboratory testing services to detect and monitor diseases. Opko also develops and markets pharmaceuticals, including treatments for chronic kidney disease, secondary hyperparathyroidism, type 2 diabetes, and obesity. Additionally, it focuses on creating immune therapies for oncology and infectious diseases, alongside developing long-acting versions of approved therapeutic proteins. Founded in 1991, Opko is based in Miami, Florida, with operations in several countries.
OPKO Health crushed consensus on both lines, posting a loss of just $0.01 per share versus an $0.11 miss estimate and delivering $163.5M in revenue against $131M forecasted. A $29.4M licensing deal with Nicoya on Rayaldee commercialization in Greater China drove the pharmaceutical segment to profitability for the first time in a year, while net losses narrowed 94% year over year to $8.4M.
Opko Health reports Q2 results after the close, with investors watching for traction in its diagnostics segment and progress on pharma commercialization.
3 Articles
Our top personal finance-related articles today. Your wallet will thank you later.
